comparemela.com

Page 2 - More Lines News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Results From Phase 3 PROpel Trial of LYNPARZA (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence

21.06.2022 - AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the results from the Phase 3 PROpel trial have been published in NEJM Evidence. Results from the trial showed that LYNPARZA in combination .

United statesNoel clarkeEliav barrCristian massacesiMerck research laboratoriesAmerican society of clinical oncologyUniversity of manchesterData monitoring committeeStatement of merck co incMerck co incExchange commissionEuropean unionSalford royal hospitalsClinical oncologyGenitourinary cancers symposiumAcute myeloid leukemia

Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA (pembrolizumab)

10.05.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data for six approved medicines and pipeline candidates in more than 25 types of cancer will be presented at the 2022 American Society of Clinical Oncology .

United statesNeoadjuvant pembrolizumabPembrolizumab pembroPembrolizumab monotherapyStatement of merck co incMerck co incExchange commissionOncology investor eventOral presentationExploratory analysisPoster presentationYear follow up of the phaseHealth related quality of lifeImpact of pembrolizumabPlus best supportive careVersus placebo

LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesUnited kingdomBruxelles capitaleCity ofJessica mcduellDaiichi sankyoAndrew tuttBrendan mcevoyRoy baynesSusan galbraithKing college londonNational surgical adjuvant breastUnion for international cancerEuropean society for medical oncology virtual plenaryFrontier science technology research foundationCompany on twitter astrazeneca

LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer

First PARP inhibitor to demonstrate overall survival benefit in early breast cancer . | March 16, 2022

United statesUnited kingdomBruxelles capitaleCity ofDaiichi sankyoAndrew tuttRoy baynesSusan galbraithKing college londonNational surgical adjuvant breastUnion for international cancerEuropean society for medical oncology virtual plenaryFrontier science technology research foundationCompany on twitter astrazenecaAmerican society of clinical oncology annual meetingBreast international group

LYNPARZA® (olaparib) approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer

WILMINGTON, Del. (BUSINESS WIRE) Mar 11, 2022

United statesUnited kingdomCity ofDave fredricksonJessica mcduellDaiichi sankyoAndrew tuttBrendan mcevoyRoy baynesKing college londonBreast cancer researchMerck research laboratoriesAmerican society of clinical oncologyUnion for international cancerDrug administrationUs national cancer institute

vimarsana © 2020. All Rights Reserved.